MissionIR Articles
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) and Aldevron Expand Manufacturing Program to Advance Oncoprex(TM)
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its entry into a new agreement with manufacturing partner Aldevron, LLC for expansion of Genprex’s…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Shareholder Letter Highlighting Oncoprex(TM) Progress, License Agreement for a Diabetes Drug Candidate and Other Achievements
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Strategic Board Appointments of Three Biotechnology and Healthcare Industry Leaders
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments, which…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Expands Leadership Team with Appointment of Accomplished Life Science Executives
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Catherine M. Vaczy as executive vice president and chief strategy officer and…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Present at the Third Annual LD Micro Virtual Conference
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that it will present at the third annual LD Micro Virtual Conference at 1:40 p.m.…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh for Potentially Curative Gene Therapy Candidate for Diabetes
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced its entry into an exclusive license agreement with the University of Pittsburgh for…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at NobleCon16 Investor Conference
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that it will present at the Noble Capital Markets 16th…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Reports Preclinical Data Showing Positive Results for Treatment of Resistant Metastatic Lung Cancers
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data at the American Association of Cancer Research…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) at Forefront to Advance Innovative Developments in Fight Against Lung Cancers
Clinical-stage gene-therapy company Genprex (NASDAQ: GNPX) is at the forefront to advance innovative developments in the war against lung cancers, testing its trademarked Oncoprex immunogene therapy. A recent article discussing this reads, “Oncoprex’s phase I…
Search Articles
Latest Articles
- BluSky AI Inc. (BSAI): Democratizing AI Through Modular Infrastructure and a New Neocloud That Scales from Startup to Enterprise
- MissionIRNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Integrates Chainlink Data Services Into Tokenized Money Market Fund
- Brera Holdings PLC (NASDAQ: BREA) Gains Outperform Rating from PartnerCap Securities, Price Target Set at $11.50
- MissionIRNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Advances Predictive Power in Cancer Drug Development
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Positioned to Drive RapidSX(TM) Toward Commercial Launch